Liminal BioSciences Inc. (LMNL)
Liminal BioSciences Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Laval, QC, CA. The stock last traded at $8.50, up 0.12% on the session, giving a market capitalisation of $27.6M. On trailing twelve-month figures it carries a trailing P/E of -0.03, a net margin of -7211.0%. Its beta of 1.03 implies it has historically moved more than the broad market.
Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials. This agent, along with its related derivatives, is undergoing investigation for potential application in treating idiopathic fibrosis affecting the lungs, liver, heart, or skin, as well as various respiratory conditions. Furthermore, Liminal is advancing antagonist programs, including G-protein coupled receptor 84 (GPR84) and Oxo-eicosanoid receptor 1 (OXER1), both of which are currently in preclinical development. Formerly known as Prometic Life Sciences Inc., the company adopted the name Liminal BioSciences Inc. in October 2019. Established in 1994, its corporate headquarters are located in Laval, Canada.
Liminal BioSciences Inc. is most often compared with the following Healthcare names: